Kura Oncology, Inc. (NASDAQ:KURA) is one of the stocks Jim Cramer offered insights on. When a caller highlighted the company’s $135 million milestone payment owing to its U.S. commercial sale of KOMZIFTI, Cramer commented:
“That’s a lot. That is a lot… Now, just understand that, yeah, they are milestone payments, not actual. Now, here’s what you have to understand. I have always felt that if you have something that is for cancer and it works, then you have to own the stock as a speculation, but just as a speculation, because it’s been such a difficult disease. J&J and Merck are the ones that are ahead if you want the majors.”
Stock market reports printed on a sheet of paper. Photo by RDNE Stock Project on Pexels
Kura Oncology, Inc. (NASDAQ:KURA) is developing targeted cancer therapies focused on genetically defined leukemias and solid tumors, with several drug candidates in clinical development. In November, the company, along with Kyowa Kirin received FDA approval for KOMZIFTI (ziftomenib), a once-daily oral targeted therapy for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. On December 8, Kura Oncology and Kyowa Kirin reported early trial results showing that KOMZIFTI combined with venetoclax and azacitidine was generally well tolerated and showed meaningful activity in AML with NPM1 mutations or KMT2A rearrangements. Gail J. Roboz, M.D., hematologist and leukemia specialist (William S. Paley Professor in Clinical Medicine) said:
“In relapsed/refractory NPM1-m and KMT2A-r AML, overall response rates of 65% and 41% were observed, rising to 83% and 70% in venetoclax-naïve patients, underscoring ziftomenib’s potential benefit even in challenging settings. Importantly, inclusion of ziftomenib was generally well tolerated, paving the way for its integration into front-line and relapsed/refractory regimens through ongoing registrational trials.”
While we acknowledge the potential of KURA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
